[
  {
    "ts": null,
    "headline": "Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight",
    "summary": "Incyte Corporation (NASDAQ:INCY) is one of the top most undervalued biotech stocks to buy now. Wells Fargo upgraded Incyte Corporation (NASDAQ:INCY) to Overweight from Equal Weight on August 6, raising the price target to $89 from $67. The firm told investors in a research note that it believes Incyte Corporation’s (NASDAQ:INCY) Phase 1 update for […]",
    "url": "https://finnhub.io/api/news?id=55bdcccbe139a36debcb34793abb5a0d2e69cc1968f0987ca573f28fdef450ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755004255,
      "headline": "Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight",
      "id": 136321182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation (NASDAQ:INCY) is one of the top most undervalued biotech stocks to buy now. Wells Fargo upgraded Incyte Corporation (NASDAQ:INCY) to Overweight from Equal Weight on August 6, raising the price target to $89 from $67. The firm told investors in a research note that it believes Incyte Corporation’s (NASDAQ:INCY) Phase 1 update for […]",
      "url": "https://finnhub.io/api/news?id=55bdcccbe139a36debcb34793abb5a0d2e69cc1968f0987ca573f28fdef450ca"
    }
  }
]